New drug pacritinib takes on standard therapy for rare leukemia
NCT ID NCT07033598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial compares pacritinib to the standard drug hydroxyurea in 66 adults with advanced proliferative chronic myelomonocytic leukemia (CMML). The goal is to see if pacritinib improves blood cell counts, reduces spleen size, and controls symptoms better than hydroxyurea. Participants take either drug for up to 48 weeks and are followed for a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pacritinib
What this could lead to
If pacritinib works better than hydroxyurea, it could offer a new treatment option for people with advanced chronic myelomonocytic leukemia, potentially improving blood counts and reducing spleen size.
What could go wrong
This is a phase 2 trial with only 66 participants, so results are still early. Pacritinib may not prove more effective than hydroxyurea, and side effects could be similar or worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA MYELOMONOCYTIC CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Email: •••••@•••••
Contact
-
Winship Cancer Institute at Emory
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••